The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Arthroplasty, Replacement, Hip

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Arthroplasty, Replacement, Hip


High impact information on Arthroplasty, Replacement, Hip


Chemical compound and disease context of Arthroplasty, Replacement, Hip


Biological context of Arthroplasty, Replacement, Hip


Anatomical context of Arthroplasty, Replacement, Hip


Associations of Arthroplasty, Replacement, Hip with chemical compounds


Gene context of Arthroplasty, Replacement, Hip


Analytical, diagnostic and therapeutic context of Arthroplasty, Replacement, Hip


  1. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. Leyvraz, P.F., Richard, J., Bachmann, F., Van Melle, G., Treyvaud, J.M., Livio, J.J., Candardjis, G. N. Engl. J. Med. (1983) [Pubmed]
  2. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. Bergqvist, D., Benoni, G., Björgell, O., Fredin, H., Hedlundh, U., Nicolas, S., Nilsson, P., Nylander, G. N. Engl. J. Med. (1996) [Pubmed]
  3. Lower risk of thromboembolic disease after total hip replacement with non-cemented than with cemented prostheses. Francis, C.W., Marder, V.J., Evarts, C.M. Lancet (1986) [Pubmed]
  4. Hormonal and hemodynamic profile of an anaphylactic reaction in man. Moss, J., Fahmy, N.R., Sunder, N., Beaven, M.A. Circulation (1981) [Pubmed]
  5. Implant design affects markers of bone resorption and formation in total hip replacement. Qureshi, A.A., Virdi, A.S., Didonna, M.L., Jacobs, J.J., Masuda, K., Paprosky, W.P., Thonar, E.J., Sumner, D.R. J. Bone Miner. Res. (2002) [Pubmed]
  6. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. Turpie, A.G., Gallus, A.S., Hoek, J.A. N. Engl. J. Med. (2001) [Pubmed]
  7. Systemic absorption of neomycin irrigating solution. Weinstein, A.J., McHenry, M.C., Gavan, T.L. JAMA (1977) [Pubmed]
  8. Long-term results of prophylactic cefazolin versus placebo in total hip replacement. Doyon, F., Evrard, J., Mazas, F., Hill, C. Lancet (1987) [Pubmed]
  9. Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis. Kassis, J., Hirsh, J., Podor, T.J. Blood (1992) [Pubmed]
  10. Loosening of a revision total hip replacement in a 60-year-old woman with longstanding rheumatoid arthritis. Gravallese, E.M., Weissman, B.N., Brodsky, G., Maguire, J. Arthritis Rheum. (1995) [Pubmed]
  11. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. Eriksson, B.I., Wille-Jørgensen, P., Kälebo, P., Mouret, P., Rosencher, N., Bösch, P., Baur, M., Ekman, S., Bach, D., Lindbratt, S., Close, P. N. Engl. J. Med. (1997) [Pubmed]
  12. A comparative analysis of warfarin and low-dose heparin as thromboembolism prophylaxis in total hip replacement patinets. Ritter, M.A., HamiltonCW, n.u.l.l. Ann. Surg. (1975) [Pubmed]
  13. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. Chen, J.J., Frame, D.G., White, T.J. Arch. Intern. Med. (1998) [Pubmed]
  14. Clinical experience with ximelagatran in orthopaedic surgery. Eriksson, B. Drugs (2004) [Pubmed]
  15. Preoperative irradiation versus the use of nonsteroidal anti-inflammatory drugs for prevention of heterotopic ossification following total hip replacement: the results of a randomized trial. Kölbl, O., Knelles, D., Barthel, T., Raunecker, F., Flentje, M., Eulert, J. Int. J. Radiat. Oncol. Biol. Phys. (1998) [Pubmed]
  16. Effects on coagulation and fibrinolysis of desmopressin in patients undergoing total hip replacement. Flordal, P.A., Ljungström, K.G., Svensson, J., Ekman, B., Neander, G. Thromb. Haemost. (1991) [Pubmed]
  17. Heparin therapy. Regimens and treatment considerations. Hyers, T.M. Drugs (1992) [Pubmed]
  18. Comparative pharmacokinetics of cefamandole, cefuroxime and cephradine during total hip replacement. Davies, A.J., Lockley, R.M., Jones, A., el-Safty, M., Clothier, J.C. J. Antimicrob. Chemother. (1986) [Pubmed]
  19. Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement. Weissberger, A.J., Anastasiadis, A.D., Sturgess, I., Martin, F.C., Smith, M.A., Sönksen, P.H. Clin. Endocrinol. (Oxf) (2003) [Pubmed]
  20. Methylmethacrylate metabolism in man. The hydrolysis of methylmethacrylate to methacrylic acid during total hip replacement. Crout, D.H., Corkill, J.A., James, M.L., Ling, R.S. Clin. Orthop. Relat. Res. (1979) [Pubmed]
  21. Androstenedione metabolism in cultured human osteoblast-like cells. Bruch, H.R., Wolf, L., Budde, R., Romalo, G., Schweikert, H.U. J. Clin. Endocrinol. Metab. (1992) [Pubmed]
  22. Quality of washed salvaged red blood cells during total hip replacement: a comparison between the use of heparin and citrate as anticoagulants. Mortelmans, Y., Vermaut, G., Van Aken, H., Goossens, W., Boogaerts, M. Anesth. Analg. (1994) [Pubmed]
  23. Total hip replacement induces injury to remote veins in a canine model. Stewart, G.J., Alburger, P.D., Stone, E.A., Soszka, T.W. The Journal of bone and joint surgery. American volume. (1983) [Pubmed]
  24. Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement. Amstutz, H.C., Friscia, D.A., Dorey, F., Carney, B.T. The Journal of bone and joint surgery. American volume. (1989) [Pubmed]
  25. Thromboplastin activity of blood monocytes after total hip replacement. Nygaard, O.P., Unneberg, K., Reikerås, O., Osterud, B. Scand. J. Clin. Lab. Invest. (1990) [Pubmed]
  26. Recombinant hirudin compared with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. Robb, J. N. Engl. J. Med. (1998) [Pubmed]
  27. Muscle and plasma amino acids after injury: the role of inactivity. Askanazi, J., Elwyn, D.H., Kinney, J.M., Gump, F.E., Michelsen, C.B., Stinchfield, F.E., Fürst, P., Vinnars, E., Bergström, J. Ann. Surg. (1978) [Pubmed]
  28. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Eriksson, B.I., Dahl, O.E. Drugs (2004) [Pubmed]
  29. Preoperative identification of patients at high risk of deep venous thrombosis despite prophylaxis in total hip replacement. Rocha, E., Alfaro, M.J., Páramo, J.A., Cañadell, J.M. Thromb. Haemost. (1988) [Pubmed]
  30. Cathepsin G and alpha 1-antichymotrypsin in the local host reaction to loosening of total hip prostheses. Takagi, M., Konttinen, Y.T., Santavirta, S., Kangaspunta, P., Suda, A., Rokkanen, P. The Journal of bone and joint surgery. American volume. (1995) [Pubmed]
  31. The plasminogen activation system is upregulated in loosening of total hip prostheses. Nordsletten, L., Buo, L., Takagi, M., Konttinen, Y.T., Yamakawa, M., Santavirta, S., Aasen, A.O. Acta orthopaedica Scandinavica. (1996) [Pubmed]
  32. Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis. Diehl, P., Hantke, B., Hennig, M., Tschesche, H., Mittelmeier, W., Schmitt, M., Muehlenweg, B. Int. J. Mol. Med. (2004) [Pubmed]
  33. Changes in the concentration of plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) after total joint replacement in patients with arthritis. Omura, K., Takahashi, M., Omura, T., Miyamoto, S., Kushida, K., Sano, Y., Miura, M., Nagano, A. Clin. Rheumatol. (2002) [Pubmed]
  34. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis. Páramo, J.A., Alfaro, M.J., Rocha, E. Thromb. Haemost. (1985) [Pubmed]
  35. Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Planès, A., Samama, M.M., Lensing, A.W., Büller, H.R., Barre, J., Vochelle, N., Beau, B. Thromb. Haemost. (1999) [Pubmed]
  36. Intravenous diclofenac coupled with PCA fentanyl for pain relief after total hip replacement. Laitinen, J., Nuutinen, L. Anesthesiology (1992) [Pubmed]
  37. Extradural clonidine infusions for analgesia after total hip replacement. Carabine, U.A., Milligan, K.R., Mulholland, D., Moore, J. British journal of anaesthesia. (1992) [Pubmed]
  38. Single versus staged epidural injections of 0.75% bupivacaine: pharmacokinetic and pharmacodynamic effects. Sharrock, N.E., Mineo, R., Stanton, J., Ennis, W.J., Urmey, W.F., Arthur, G.R. Anesth. Analg. (1994) [Pubmed]
WikiGenes - Universities